Somnigroup International Inc (Somnigroup) formerly known as Tempur Sealy International Inc, is a manufacturer, distributor, and retailer of bedding products. It includes bedding products, such as mattresses, pillows, and other bedding accessories. The company operates through owned businesses such as Tempur Sealy, Mattress Firm, and Dreams, and offers a range of bedding products under brands such as Tempur-Pedic, Sealy, and Stearns & Foster. Somnigroup serves industries including retail, hospitality, and healthcare.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on development of new products and improving existing products. As of December 2025, the company operated four research and development centers, three located in the US and one in Denmark, focused on technology and product development. The company also operates a product testing facility that conducts numerous consumer tests annually, emphasizing a consumer-research driven approach to innovation to create best-in-class products. As of December 31, 2025, it hold over one thousand US and foreign patents. In FY2025, the company incurred expenses of US$32.9 million on R&D activities, which as a percentage of revenue, stood at 0.4%.